I. Craig Henderson, MD


Adjunct Professor, Department of Medicine (Hematology/Oncology), UCSF


Phone: (415) 674-5148 (voice)
Box 1710, UCSF
San Francisco, CA 94143-1710

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Breast Oncology


Grinnell College, Grinnell, IA, A.B., 1963
Columbia University, College of Physicians & Surgeons, New York, NY, M.D., 1970

Professional Experience

  • 1970-1972
    Intern and Resident in Medicine, Presbyterian Hospital, New York, NY
  • 1972-1974
    Research Associate, Viral Leukemia and Lymphoma Branch, NCI, Bethesda
  • 1974-1975
    Clinical Fellow in Medicine, Sydney Farber Cancer Inst., Harvard Medical School (HMS)
  • 1975-1976
    Instructor of Medicine, Sydney Farber Cancer Inst., HMS
  • 1976-1984
    Assistant Professor of Medicine, Dana-Farber Cancer Inst., HMS
  • 1979-1992
    Founder and Director, Breast Evaluation Center, Dana-Farber Cancer Inst., Boston
  • 1981-1982
    Consultant, Cancer Unit, World Health Organization, Geneva, Switzerland
  • 1982-1996
    Breast Core Committee, Cancer and Acute Leukemia Group B (Chairman 1990-1995)
  • 1983-1993
    Subcommittee on Antineoplastic and Immunosuppressive Drugs, Committee on Essential Drugs, World Health Organization (Chairman 1983)
  • 1984-1992
    Associate Professor of Medicine, Dana-Farber Cancer Inst., HMS, Boston
  • 1985-1993
    World Health Organization Expert Advisory Panel on Cancer, Geneva
  • 1985-1995
    Early Breast Cancer Trialists Collaborative Group (Oxford Overview Group) (Chairman 1985-1995)
  • 1987-1990
    United States Congressional Office of Technology Assessment: Working Group on Immuno-Augmentative Therapy
  • 1988-1994
    National Task Force on Breast Cancer Control, American Cancer Society
  • 1989-1992
    Member, Oncologic Drugs Advisory Committee, FDA (Chairman 1990-1992)
  • 1991-1993
    Education Committee, American Society of Clinical Oncology
  • 1992-1995
    Professor of Medicine, University of California San Francisco (UCSF)
  • 1992-1995
    Chief, Division of Oncology, Moffitt-Long-Mt. Zion
  • 1992-1995
    Assoc. Director for Clinical Oncology in Comprehensive Cancer Center, UCSF (Interim)
  • 1992-1996
    Founder, PI, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
  • 1996-present
    Steering Committee Member, Bay Area Breast Cancer Translational Research Program (NIH Specialized Program of Research Excellence, SPORE)
  • 1995-present
    Adjunct Professor of Medicine, University of California San Francisco
  • 1995-1999
    CEO and Chairman, SEQUUS Pharmaceuticals, Menlo Park Ca.
  • 1999-present
    Senior Consultant, Alza Corporation, Mountain View, Ca. (Director 1999-2001)
  • 2000-present
    Institute of Medicine Committee on Technologies for the Early Detection of Breast Cancer (Vice Chairman)
  • 2000-present
    Breast Cancer Research Council of the State of California
  • 2001-present
    President and Director, Access Oncology, Inc., New York City, NY

Honors & Awards

  • 1966
    Merck, Sharpe and Dohme International Fellow, Columbia University
  • 1970
    Research Prize, Columbia University Medical Society
  • 1988
    Fellow, American College of Physicians
  • 1987
    Henrietta Banting Memorial Lecturer, Canada
  • 1992
    General Motors Cancer Research Foundation Lecturer, The Royal Marsden
  • 1992
    Bernard L. Schwartz Lecturer, Scripps Memorial Hospitals
  • 1993
    British Oncological Association Lecturer, United Kingdom
  • 1993
    Distinguished Alumnus Award, Grinnell College
  • 1994
    Doctorate of Science, Grinnell College
  • 1996
    Wendell Scott Lecture, American College of Radiology
  • 1997
    Fellow, Royal College of Physicians (Edinburgh)
  • 1999
    Outstanding Industry Leader in Medical Research, California Pacific Medical Center Research Institute
  • 2000
    Millennium Award from Bristol-Myers Squibb Oncology and Susan G. Komen Breast Cancer Foundation

Selected Publications

  1. Bisphosphonates: game changers? Oncology (Williston Park). 2015 Jan 15; 29(1).
    View on PubMed
  2. Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park). 2012 Nov; 26(11):1035, 1039.
    View on PubMed
  3. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 1; 17(15):5170-8.
    View on PubMed
  4. Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park). 2011 Feb; 25(2):115-24, 127.
    View on PubMed
  5. Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat. 2010 Aug; 123(1):159-62.
    View on PubMed
  6. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-63.
    View on PubMed
  7. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13.
    View on PubMed
  8. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72.
    View on PubMed
  9. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View on PubMed
  10. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
    View on PubMed
  11. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
    View on PubMed
  12. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704.
    View on PubMed
  13. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007 Jul; 7(7):919-43.
    View on PubMed
  14. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8.
    View on PubMed
  15. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
    View on PubMed
  16. Axillary surgery: clinical judgment required. J Clin Oncol. 2006 Jan 20; 24(3):325-6.
    View on PubMed
  17. Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res. 2005; 7(6):271-5.
    View on PubMed
  18. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. Clin Breast Cancer. 2005 Aug; 6(3):206-15.
    View on PubMed
  19. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View on PubMed
  20. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 1; 23(19):4287-97.
    View on PubMed

Go to UCSF Profiles, powered by CTSI